IL306018A - A preparation containing a cyclic peptide compound and a method for its production - Google Patents

A preparation containing a cyclic peptide compound and a method for its production

Info

Publication number
IL306018A
IL306018A IL306018A IL30601823A IL306018A IL 306018 A IL306018 A IL 306018A IL 306018 A IL306018 A IL 306018A IL 30601823 A IL30601823 A IL 30601823A IL 306018 A IL306018 A IL 306018A
Authority
IL
Israel
Prior art keywords
compound
formulation
composition according
added
weight
Prior art date
Application number
IL306018A
Other languages
English (en)
Hebrew (he)
Inventor
Takamitsu Ueto
Yukari Kuboki
Original Assignee
Chugai Pharmaceutical Co Ltd
Takamitsu Ueto
Yukari Kuboki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd, Takamitsu Ueto, Yukari Kuboki filed Critical Chugai Pharmaceutical Co Ltd
Publication of IL306018A publication Critical patent/IL306018A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL306018A 2021-05-07 2022-05-06 A preparation containing a cyclic peptide compound and a method for its production IL306018A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021079015 2021-05-07
PCT/JP2022/019540 WO2022234850A1 (ja) 2021-05-07 2022-05-06 環状ペプチド化合物を含む製剤及びその製造方法

Publications (1)

Publication Number Publication Date
IL306018A true IL306018A (en) 2023-11-01

Family

ID=83932759

Family Applications (1)

Application Number Title Priority Date Filing Date
IL306018A IL306018A (en) 2021-05-07 2022-05-06 A preparation containing a cyclic peptide compound and a method for its production

Country Status (12)

Country Link
US (1) US20240366711A1 (enExample)
EP (1) EP4299069A4 (enExample)
JP (2) JP7181442B1 (enExample)
KR (2) KR20230169093A (enExample)
CN (1) CN117241817A (enExample)
AU (1) AU2022270498A1 (enExample)
BR (1) BR112023019622A2 (enExample)
CA (1) CA3219090A1 (enExample)
IL (1) IL306018A (enExample)
MX (1) MX2023013099A (enExample)
TW (1) TW202308679A (enExample)
WO (1) WO2022234850A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI852183B (zh) 2011-12-28 2024-08-11 日商中外製藥股份有限公司 胜肽化合物之環化方法
EP4043478A4 (en) 2019-11-07 2024-01-03 Chugai Seiyaku Kabushiki Kaisha CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITING ACTION
AR125800A1 (es) 2021-05-07 2023-08-16 Chugai Pharmaceutical Co Ltd Métodos para producir compuestos cíclicos que comprendan residuos de aminoácidos sustituidos con n
IL316253A (en) 2022-05-06 2025-01-01 Chugai Pharmaceutical Co Ltd A cyclic compound with selective KRAS inhibitory effect on HRAS and NRAS
US20260132169A1 (en) * 2022-10-20 2026-05-14 Chugai Seiyaku Kabushiki Kaisha Method for producing cyclic peptide crystals
TW202506706A (zh) * 2023-04-20 2025-02-16 日商中外製藥股份有限公司 環狀胜肽化合物的製造方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012112319A1 (en) * 2011-02-04 2012-08-23 Aegis Therapeutics, Llc Orally bioavailable peptide drug compositions and methods thereof
ES2586411T3 (es) 2011-03-04 2016-10-14 New York University Macrociclos sustitutos de enlace de hidrógeno como moduladores de Ras
TWI852183B (zh) * 2011-12-28 2024-08-11 日商中外製藥股份有限公司 胜肽化合物之環化方法
WO2016071515A1 (en) 2014-11-07 2016-05-12 Sigmoid Pharma Limited Compositions comprising cyclosporin
EP3442991A4 (en) 2016-04-15 2019-11-20 RA Pharmaceuticals, Inc. RAS-BINDING PEPTIDES AND METHODS OF USE
US10808010B2 (en) 2016-08-11 2020-10-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide inhibitors of phosphoglycerate mutase and methods of use
EP3636807A4 (en) 2017-06-09 2021-07-28 Chugai Seiyaku Kabushiki Kaisha CYCLIC PEPTIDE COMPOUND WITH HIGH MEMBRANE PERMEABILITY AND LIBRARY WITH IT
WO2020122182A1 (ja) 2018-12-12 2020-06-18 中外製薬株式会社 分子内水素結合可能な官能基を有するアミノ酸とそれらのアミノ酸を含むペプチド化合物、およびそれらの製造方法
EP4043478A4 (en) * 2019-11-07 2024-01-03 Chugai Seiyaku Kabushiki Kaisha CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITING ACTION
AR125800A1 (es) * 2021-05-07 2023-08-16 Chugai Pharmaceutical Co Ltd Métodos para producir compuestos cíclicos que comprendan residuos de aminoácidos sustituidos con n

Also Published As

Publication number Publication date
AU2022270498A1 (en) 2023-10-05
JP7181442B1 (ja) 2022-11-30
TW202308679A (zh) 2023-03-01
JP2023015334A (ja) 2023-01-31
EP4299069A4 (en) 2025-03-05
CN117241817A (zh) 2023-12-15
US20240366711A1 (en) 2024-11-07
WO2022234850A1 (ja) 2022-11-10
KR102582225B1 (ko) 2023-09-22
MX2023013099A (es) 2023-11-17
KR20230169093A (ko) 2023-12-15
JPWO2022234850A1 (enExample) 2022-11-10
CA3219090A1 (en) 2022-11-10
KR20230020548A (ko) 2023-02-10
BR112023019622A2 (pt) 2023-11-14
EP4299069A1 (en) 2024-01-03

Similar Documents

Publication Publication Date Title
US20240366711A1 (en) Preparation containing cyclic peptide compound and method for producing same
TWI516263B (zh) 經取代之5-氟-1h-吡唑并吡啶類及其用途
ES2929526T3 (es) Sal cristalina de L-arginina del ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para su uso en trastornos asociados al receptor S1P1
EP2310363B1 (en) Anticancer oral formulation
CA2803699C (en) Salt and solvates of a tetrahydroisoquinoline derivative
EP4249496A1 (en) Method for supporting amino acid on resin for solid-phase synthesis
EP4031133B1 (en) Pyruvate kinase r (pkr) activating compositions
EA027869B1 (ru) Стабилизированная композиция такролимуса
US20190153024A1 (en) Novel salts and polymorphs of scy-078
TW201609717A (zh) Plk-4抑制劑之鹽和結晶形式
RU2744264C2 (ru) Кристаллическая форма соединения, подавляющего активность протеинкиназы, и её применение
WO2025040810A1 (en) Therapeutic compounds, a method of manufacturing thereof as well as uses thereof
Huang et al. Simultaneously improving the physicochemical and pharmacokinetic properties of vemurafenib through cocrystallization strategy
Wu et al. Preparation, characterization and pharmacokinetics of Cucurbitacin B solid dispersion
KR20260023581A (ko) (e)-n-히드록시-3-(1-(페닐술포닐)인돌린-5-일)아크릴아미드의 결정 형태
EA049912B1 (ru) Препарат, содержащий циклическое пептидное соединение, и способы его приготовления
HK40096081A (en) Preparation containing cyclic peptide compound and method for producing same
CA3218470A1 (en) Polymorph of imidazolidinone compound, preparation method therefor and use thereof
WO2021055863A1 (en) Pyruvate kinase r (pkr) activating compositions
WO2025235577A1 (en) Forms and formulations of substituted 3-((3-amino)piperidine-2,6-dione compounds
JP2007512333A (ja) 縮合ピロロカルバゾール含有粒子形成組成物
HK40079381A (en) Novel salts and polymorphs of scy-078
AU2024328199A1 (en) Therapeutic compounds, a method of manufacturing thereof as well as uses thereof
CN119119048A (zh) 一种化合物的晶型及其制备方法和应用
HK40078162B (en) Pyruvate kinase r (pkr) activating compositions